EYSINS, Switzerland, March 11, 2013 /PRNewswire/ --
Biosafe is proud to announce that it is celebrating a landmark, with the manufacture of the one millionth proprietary SEPAX separation chamber for cord blood processing kits. This milestone confirms that SEPAX has become the industry standard in cord blood banking, as it has been used in almost half of worldwide processing procedures for cord blood inventory.
(Logo: http://photos.prnewswire.com/prnh/20121119/574143 )
Commenting on reaching the one million kit landmark, Founder and Chairman of the Board Claude Fell said: "According to the Worldwide Network for Blood and Marrow Transplantation, over one million stem cell transplants have now been performed and we are proud to be part of the chain enabling cell therapy treatment through innovative cell processing applications. The Biosafe one million separation chamber landmark is likewise a recognition of the commitment of our employees to delivering state of the art quality and reliability in the design and manufacture of our cell separation kits."
SEPAX also offers a wide range of applications in the rapidly developing regenerative medicine area. It is used in a point of care environment such as cardiovascular and orthopedic, while in biotechnology and pharmaceutical processes it provides a versatile cell processing platform. Applications range from peripheral blood stem cell to bone marrow density gradient separation, as well as cell washing.
About the Biosafe Group
Founded in 1997, the Biosafe Group is active in the design, manufacture and marketing of automated cell processing systems. Headquarted in Switzerland and privately-owned, the Biosafe Group operates through regional subsidiaries (Geneva, Houston, Hong-Kong and Shanghai) and is present in more than 45 countries, either directly or through distributors.
For further information:
Christopher Bolton
CFO
Biosafe Group
+41-21-365-27-27
christopher.bolton@biosafe.ch
http://www.biosafe.ch
Share this article